ADVENTRX Pharmaceuticals, Inc. (AMEX:ANX) announced
today that Brian M. Culley, vice president of business development,
will present a corporate overview at the 13th Annual Euro-Biotech
Forum on June 29 at 2:45 p.m. Central European Summer Time. The
Euro-Biotech Forum is an industry partnering meeting for American and
European life science companies. The conference takes place June
27-29, 2006, at the Westin Paris. More information about the
conference can be found on the conference Web site at
http://www.eurobiotechforum.com.
About ADVENTRX
ADVENTRX Pharmaceuticals is a biopharmaceutical research and
development company focused on introducing treatments for cancer and
infectious disease that surpass the performance and safety of existing
drugs, by addressing significant problems such as drug metabolism,
toxicity, bioavailability and resistance. More information can be
found on the Company's Web site at www.adventrx.com.
Forward-Looking Statement
This press release contains forward-looking statements, within the
meaning of the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995, regarding ADVENTRX. Such statements are
made based on management's current expectations and beliefs. Actual
results may vary from those currently anticipated based upon a number
of factors, including uncertainties inherent in the drug development
process, the timing and success of clinical trials, the validity of
research results, and the receipt of necessary approvals from the FDA
and other regulatory agencies. For a discussion of such risks and
uncertainties, which could cause actual results to differ from those
contained in the forward-looking statements regarding ADVENTRX, see
the section titled "Risk Factors" in ADVENTRX's last annual report on
Form 10-K and its Quarterly Reports on Form 10-Q, as well as other
reports that ADVENTRX files from time to time with the Securities and
Exchange Commission. All forward-looking statements regarding ADVENTRX
are qualified in their entirety by this cautionary statement. ADVENTRX
undertakes no obligation to release publicly any revisions to
forward-looking statements to reflect events or circumstances which
occur after the date hereof.
